{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T03:14:41Z","timestamp":1789442081985,"version":"build-2803163510"},"reference-count":63,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.clml.2024.11.012","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T11:42:16Z","timestamp":1732275736000},"page":"309-315","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Comprehensive Review of Bispecific Antibody Constructs In Multiple Myeloma: Affinities, Dosing Strategies and Future Perspectives"],"prefix":"10.1016","volume":"25","author":[{"given":"Johannes M.","family":"Waldschmidt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Rasche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Martin","family":"Kort\u00fcm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10192","key":"10.1016\/j.clml.2024.11.012_bib0001","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.clml.2024.11.012_bib0002","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, Bortezomib, Lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.clml.2024.11.012_bib0003","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2024.11.012_bib0004","unstructured":"Spicka I et al. Real-world patient characteristics and survival outcomes of lenalidomide refractory vs. lenalidomide exposed RRMM patients in the HONEUR federated data network. https:\/\/library.ehaweb.org\/eha\/2023\/eha2023congress\/386773\/ivan.spicka.real-world.patient.characteristics.and.survival.outcomes.of.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Ace_id%3D2489%2Aot_id%3D27922%2Amarker%3D4178 (Accessed September 8, 2024)."},{"issue":"8","key":"10.1016\/j.clml.2024.11.012_bib0005","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/S1470-2045(24)00282-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial","volume":"25","author":"Moreau","year":"2024","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.clml.2024.11.012_bib0006","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41571-024-00905-y","article-title":"Bispecific and multispecific antibodies in oncology: opportunities and challenges","volume":"21","author":"Goebeler","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"20","key":"10.1016\/j.clml.2024.11.012_bib0007","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","article-title":"Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma","volume":"123","author":"Tai","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.11.012_bib0008","unstructured":"FDA Resources. FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-teclistamab-cqyv-relapsed-or-refractory-multiple-myeloma (Accessed September 12, 2024)."},{"key":"10.1016\/j.clml.2024.11.012_bib0009","unstructured":"FDA Resources. FDA grants accelerated approval to talquetamab-tgvs for relapsed or refractory multiple m eloma. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-talquetamab-tgvs-relapsed-or-refractory-multiple-myeloma (Accessed September 12, 2024)."},{"key":"10.1016\/j.clml.2024.11.012_bib0010","unstructured":"FDA Resources. FDA grants accelerated approval to elranatamab-bcmm for multiple myeloma. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-elranatamab-bcmm-multiple-myeloma (Accessed September 12, 2024)."},{"issue":"22","key":"10.1016\/j.clml.2024.11.012_bib0011","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for treatment of relapsed\/refractory multiple myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1016\/j.clml.2024.11.012_bib0012","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.22.01504","article-title":"A phase I first-in-Human study of ABBV-383, a B-cell maturation antigen \u00d7 CD3 bispecific T-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma","volume":"40","author":"D'Souza","year":"2022","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.11.012_bib0013","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1182\/blood-2022-159009","article-title":"Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-cell maturation antigen (BCMA) x CD3 T-cell engager (TCE), in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): results from a phase 1 first-in-Human clinical study","volume":"140","author":"Wong","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.11.012_bib0014","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S2152-2650(23)01572-0","article-title":"OA-05 efficacy of forimtamig, a GPRC5DxCD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM): analysis of patient and disease-related factors associated with responses","volume":"23","author":"Harrison","year":"2023","journal-title":"Clin Lymph, Myel Leuke"},{"key":"10.1016\/j.clml.2024.11.012_bib0015","unstructured":"Kumar S, Bachier CR, Cavo M, et al. Cevostmab in patients with RRMM who are triple-class refractory and have received a prior BCMA-targeted ADC or CAR T-cell: initial results from the phase I\/II CAMMA 2 study. https:\/\/library.ehaweb.org\/eha\/2024\/eha2024-congress\/422314\/shaji.kumar.cevostamab.in.patients.with.rrmm.who.are.triple-class.refractory.html. (Accessed September 8, 2024)."},{"key":"10.1016\/j.clml.2024.11.012_bib0016","unstructured":"Tecvayli | European Medicines Agency (EMA). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/tecvayli (2022, Accessed September 20, 2024)."},{"issue":"10301","key":"10.1016\/j.clml.2024.11.012_bib0017","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen\u2008\u00d7\u2008CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.clml.2024.11.012_bib0018","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"16_suppl","key":"10.1016\/j.clml.2024.11.012_bib0019","doi-asserted-by":"crossref","first-page":"7517","DOI":"10.1200\/JCO.2024.42.16_suppl.7517","article-title":"Longer-term follow-up of patients (pts) receiving prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) in the phase 1\/2 MajesTEC-1 study of teclistamab in relapsed\/refractory multiple myeloma (RRMM)","volume":"42","author":"van de Donk","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clml.2024.11.012_bib0020","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","article-title":"Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial","volume":"29","author":"Bahlis","year":"2023","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.clml.2024.11.012_bib0021","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"16_suppl","key":"10.1016\/j.clml.2024.11.012_bib0022","doi-asserted-by":"crossref","first-page":"7531","DOI":"10.1200\/JCO.2024.42.16_suppl.7531","article-title":"Efficacy, safety, and determination of RP2D of ABBV-383, a BCMA bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"42","author":"Rodriguez Valdes","year":"2024","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.clml.2024.11.012_bib0023","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.11.012_bib0024","doi-asserted-by":"crossref","unstructured":"Rasche L et al. Long-term efficacy and safety results from the phase 1\/2 MonumenTAL-1 study of talquetamab a GPRC5D\u00d7CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma. https:\/\/library.ehaweb.org\/eha\/2024\/eha2024-congress\/420979\/leo.rasche.long-term.efficacy.and.safety.results.from.the.phase.1.2.html (Accessed September 8, 2024).","DOI":"10.1016\/S2152-2650(24)00976-5"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.11.012_bib0025","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1182\/blood-2023-187242","article-title":"Updated results of Talquetamab, a GPRC5D\u00d7CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma with prior exposure to T-cell redirecting therapies: results of the phase 1\/2 MonumenTAL-1 study","volume":"142","author":"Jakubowiak","year":"2023","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2024.11.012_bib0026","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1158\/1535-7163.MCT-12-0087","article-title":"FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma","volume":"11","author":"Elkins","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.11.012_bib0027","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1182\/blood-2022-157547","article-title":"Enduring responses after 1-year, fixed-duration Cevostamab therapy in patients with relapsed\/refractory multiple myeloma: early experience from a phase I study","volume":"140","author":"Lesokhin","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2024.11.012_bib0028","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","article-title":"IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"4","author":"Lancman","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"16_suppl","key":"10.1016\/j.clml.2024.11.012_bib0029","doi-asserted-by":"crossref","first-page":"8020","DOI":"10.1200\/JCO.2023.41.16_suppl.8020","article-title":"Analysis of infections and parameters of humoral immunity in patients (pts) with relapsed\/refractory multiple myeloma (RRMM) treated with talquetamab (tal) monotherapy in MonumenTAL-1","volume":"41","author":"Rodr\u00edguez-Otero","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clml.2024.11.012_bib0030","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.clml.2024.05.003","article-title":"Clinical management of patients with relapsed\/refractory multiple myeloma treated with Talquetamab","volume":"24","author":"Chari","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"10.1016\/j.clml.2024.11.012_bib0031","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1046\/j.0022-202X.2004.12628.x","article-title":"The RAIG family member, GPRC5D, is associated with hard-keratinized structures","volume":"122","author":"Inoue","year":"2004","journal-title":"J Invest Dermatol"},{"issue":"6","key":"10.1016\/j.clml.2024.11.012_bib0032","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s11899-024-00740-z","article-title":"Management of toxicities associated with BCMA, GPRC5D, and FcRH5-targeting bispecific antibodies in multiple myeloma","volume":"19","author":"Pan","year":"2024","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.clml.2024.11.012_bib0033","unstructured":"Kumar S et al. Cevostmab in patients with RRMM who are triple-class refractory and have received a prior BCMA-targeted ADC or CAR T-cell: initial results from the phase I\/II CAMMA 2 study. https:\/\/library.ehaweb.org\/eha\/2024\/eha2024-congress\/422314\/shaji.kumar.cevostamab.in.patients.with.rrmm.who.are.triple-class.refractory.html (Accessed September 8, 2024)."},{"key":"10.1016\/j.clml.2024.11.012_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.copbio.2022.102799","article-title":"Considerations for design, manufacture, and delivery for effective and safe T-cell engager therapies","author":"Arvedson","year":"2022","journal-title":"Curr Opin Biotechnol"},{"issue":"14","key":"10.1016\/j.clml.2024.11.012_bib0035","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1002\/cncr.32909","article-title":"The BiTE (bispecific T-cell engager) platform: development and future potential of a targeted immuno-oncology therapy across tumor types","volume":"126","author":"Einsele","year":"2020","journal-title":"Cancer"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.11.012_bib0036","doi-asserted-by":"crossref","first-page":"4746","DOI":"10.1182\/blood-2023-177968","article-title":"Patterns of response to 200 Mg Linvoseltamab in patients with relapsed\/refractory multiple myeloma: longer follow-up of the Linker-MM1 study","volume":"142","author":"Jagannath","year":"2023","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.clml.2024.11.012_bib0037","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1182\/blood.2024024590","article-title":"Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma","volume":"144","author":"John","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2024.11.012_bib0038","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2024.11.012_bib0039","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene Vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the Myeloma CAR T Consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2024.11.012_bib0040","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-023-00886-8","article-title":"Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy","volume":"13","author":"Ferreri","year":"2023","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2024.11.012_bib0041","unstructured":"Waldschmidt J, Vucinic V, W\u00e4sch R, et al. Bridging strategies for anti-BCMA CAR-T cell therapies in multiple myeloma patients with prior exposure to bispecific antibodies. https:\/\/library.ehaweb.org\/eha\/2024\/eha2024-congress\/421037\/johannes.waldschmidt.bridging.strategies.for.anti-bcma.cart.cell.therapies.in.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Ace_id%3D2552%2Aot_id%3D29201%2Amarker%3D5101%2Afeatured%3D18527 (Accessed September 8, 2024)."},{"issue":"6","key":"10.1016\/j.clml.2024.11.012_bib0042","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"issue":"22","key":"10.1016\/j.clml.2024.11.012_bib0043","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2024.11.012_bib0044","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1158\/2643-3230.BCD-22-0018","article-title":"Changes in bone marrow tumor and immune cells correlate with durability of remissions following BCMA CAR T therapy in myeloma","volume":"3","author":"Dhodapkar","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"16","key":"10.1016\/j.clml.2024.11.012_bib0045","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1182\/bloodadvances.2019000466","article-title":"Serial treatment of relapsed\/refractory multiple myeloma with different BCMA-targeting therapies","volume":"3","author":"Cohen","year":"2019","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.clml.2024.11.012_bib0046","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","article-title":"Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma","volume":"27","author":"Da Vi\u00e0","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.clml.2024.11.012_bib0047","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.clml.2024.11.012_bib0048","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"issue":"19","key":"10.1016\/j.clml.2024.11.012_bib0049","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/bloodadvances.2021004418","article-title":"Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MM","volume":"5","author":"Truger","year":"2021","journal-title":"Blood Adv"},{"issue":"Suppl","key":"10.1016\/j.clml.2024.11.012_bib0050","doi-asserted-by":"crossref","first-page":"e15362d7","DOI":"10.1097\/01.HS9.0000967672.15362.d7","article-title":"S190: First results from the REDIRECTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed\/refractory multiple myeloma (RRMM)","volume":"7","author":"Mateos","year":"2023","journal-title":"Hemasphere"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.11.012_bib0051","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1182\/blood-2023-174941","article-title":"Characterization of JNJ-79635322, a novel BCMAxGPRC5DxCD3 T-cell redirecting trispecific antibody, for the treatment of multiple myeloma","volume":"142","author":"Pillarisetti","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2024.11.012_bib0052","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1158\/2767-9764.CRC-23-0434","article-title":"Ex vivo efficacy of SAR442257 anti-CD38 trispecific T-cell engager in multiple myeloma relapsed after Daratumumab and BCMA-targeted therapies","volume":"4","author":"Keller","year":"2024","journal-title":"Cancer Res Commun"},{"issue":"5","key":"10.1016\/j.clml.2024.11.012_bib0053","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11523-023-00989-z","article-title":"Population pharmacokinetics and exposure-response with Teclistamab in patients with relapsed\/refractory multiple myeloma: results from MajesTEC-1","volume":"18","author":"Miao","year":"2023","journal-title":"Target Oncol"},{"issue":"4","key":"10.1016\/j.clml.2024.11.012_bib0054","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/bloodadvances.2022007625","article-title":"Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed\/refractory multiple myeloma","volume":"7","author":"Girgis","year":"2023","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.clml.2024.11.012_bib0055","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1038\/leu.2017.41","article-title":"Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL","volume":"31","author":"Duell","year":"2017","journal-title":"Leukemia"},{"issue":"14","key":"10.1016\/j.clml.2024.11.012_bib0056","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1158\/1078-0432.CCR-23-3333","article-title":"T-cell characteristics impact response and resistance to T-cell-redirecting bispecific antibodies in multiple myeloma","volume":"30","author":"Verkleij","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.clml.2024.11.012_bib0057","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1158\/2643-3230.BCD-21-0073","article-title":"Finding the optimal partner to pair with bispecific antibody therapy for multiple myeloma","volume":"2","author":"Louvet","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"5","key":"10.1016\/j.clml.2024.11.012_bib0058","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.apsb.2024.01.009","article-title":"Bispecific antibody drug conjugates: making 1+1>2","volume":"14","author":"Gu","year":"2024","journal-title":"Acta Pharm Sin B"},{"issue":"10","key":"10.1016\/j.clml.2024.11.012_bib0059","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.11.012_bib0060","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1182\/blood-2023-189042","article-title":"The impact of treatment-free intervals on T-cell exhaustion and clonotypic diversity in Myeloma patients treated with BCMA bispecific antibodies","volume":"142","author":"Eisele","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2024.11.012_bib0061","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/cncr.35107","article-title":"Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTec-1 study","volume":"130","author":"Nooka","year":"2024","journal-title":"Cancer"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.11.012_bib0062","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2022-157988","article-title":"RG6234, a GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): updated intravenous (IV) and first subcutaneous (SC) results from a phase I dose-escalation study","volume":"140","author":"Carlo-Stella","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.11.012_bib0063","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood-2021-147983","article-title":"Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed\/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study","volume":"138","author":"Trudel","year":"2021","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024024236?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024024236?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T15:33:01Z","timestamp":1751383981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024024236"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":63,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2152265024024236"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.11.012","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comprehensive Review of Bispecific Antibody Constructs In Multiple Myeloma: Affinities, Dosing Strategies and Future Perspectives","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}